US · 21 CFR
21 CFR 601.42
Approval with restrictions to assure safe use.
21 CFR Part 601 › Subpart E—Accelerated Approval of Biological Products for Serious or Life-Threatening Illnesses
조항 원문
(a) If FDA concludes that a biological product shown to be effective can be safely used only if distribution or use is restricted, FDA will require such postmarketing restrictions as are needed to assure safe use of the biological product, such as:
(1) Distribution restricted to certain facilities or physicians with special training or experience; or
(2) Distribution conditioned on the performance of specified medical procedures.
(b) The limitations imposed will be commensurate with the specific safety concerns presented by the biological product.
본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.
출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16